Cannabis Cures Cancer

Research in mice and on cancer cell lines demonstrates the effectiveness of cannabinoids in treating multiple forms of cancer. Cannabinoids, especially when encased in nanoparticles and delivered directly to tumors, could be very useful in curing cancer.

Cannabinoids show effectiveness in reducing growth of the following cancers in lab animals:

1. brain cancer

2. breast cancer

3. colon cancer

4. leukemia

5. liver cancer

6. lung cancer

7. oral cancer

8. pancreatic cancer

9. skin cancer

10. thyroid cancer

Cannabinoids also inhibit growth of the following cancer cells:

1. brain cancer cells

2. breast cancer cells

3. cervical cancer cells

4. cholangiocarcinoma cells

5. colorectal cancer cells

6. drug-resistant cancer cells

7. leukemia cells

8. liver cancer cells

9. lung cancer cells

10. oral cancer cells

11. pancreatic cancer cells

12. prostate cancer cells

13. thyroid cancer cells

References:

5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. (Link)

A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study. (Link)

A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. (Link)

A combined preclinical therapy of cannabinoids and temozolomide against glioma. (Link)

Anti-proliferative and anti-angiogenic effects of CB2R agonist (JWH-133) in non-small lung cancer cells (A549) and human umbilical vein endothelial cells: an in vitro investigation. (Link)

Anti-tumor activity of the novel hexahydrocannabinol analog LYR-8 in Human colorectal tumor xenograft is mediated through the inhibition of Akt and hypoxia-inducible factor-1α activation. (Link)

Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. (Link)

Antineoplastic activity of cannabinoids. (Link)

Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. (Link)

Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma. (Link)

Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. (Link)

Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. (Link)

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. (Link)

Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. (Link)

Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. (Link)

Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. (Link)

Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. (Link)

Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. (Link)

Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration. (Link)

Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. (Link)

Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2 cells via a receptor-independent mechanism. (Link)

Cannabinoid receptor as a novel target for the treatment of prostate cancer. (Link)

Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. (Link)

Cannabinoid receptors as novel targets for the treatment of melanoma. (Link)

Cannabinoids attenuate cancer pain and proliferation in a mouse model. (Link)

Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. (Link)

Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. (Link)

Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. (Link)

Cannabinoids inhibit cellular respiration of human oral cancer cells. (Link)

Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. (Link)

Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. (Link)

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. (Link)

Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. (Link)

CB2 and TRPV1 receptors mediate cannabinoid actions on MDR1 expression in multidrug resistant cells. (Link)

Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. (Link)

Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. (Link)

Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. (Link)

Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism. (Link)

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. (Link)

Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. (Link)

Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity? (Link)

Effects of butaclamol, clopenthixol, mepromazine and cannabinol stereoisomers on apoptosis induction. (Link)

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. (Link)

HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. (Link)

Induction of apoptosis by cannabinoids in prostate and colon cancer cells is phosphatase dependent. (Link)

Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells. (Link)

Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. (Link)

Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. (Link)

Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. (Link)

Inhibition of tumor angiogenesis by cannabinoids. (Link)

Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. (Link)

JunD is involved in the antiproliferative effect of Delta9-tetrahydrocannabinol on human breast cancer cells. (Link)

Local delivery of cannabinoid-loaded microparticles inhibits tumor growth in a murine xenograft model of glioblastoma multiforme. (Link)

Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. (Link)

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. (Link)

Poly-ε-caprolactone microspheres as a drug delivery system for cannabinoid administration: development, characterization and in vitro evaluation of their antitumoral efficacy. (Link)

Safety and efficacy of a novel cannabinoid chemotherapeutic, KM-233, for the treatment of high-grade glioma. (Link)

Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death. (Link)

Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action. (Link)

Synergistic cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole. (Link)

Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. (Link)

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. (Link)

Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. (Link)

Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. (Link)

The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. (Link)

The dual effects of delta(9)-tetrahydrocannabinol on cholangiocarcinoma cells: anti-invasion activity at low concentration and apoptosis induction at high concentration. (Link)

The effects of cannabinoids on P-glycoprotein transport and expression in multidrug resistant cells. (Link)

The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. (Link)

The synthetic cannabinoid WIN 55,212-2 sensitizes hepatocellular carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by activating p8/CCAAT/enhancer binding protein homologous protein (CHOP)/death receptor 5 (DR5) axis. (Link)